Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Sep;52(3):1161-1165.
doi: 10.1007/s42770-021-00498-z. Epub 2021 Apr 19.

Comparative analysis of three point-of-care lateral flow immunoassays for detection of anti-SARS-CoV-2 antibodies: data from 100 healthcare workers in Brazil

Danielle Dias Conte  1 , Joseane Mayara Almeida Carvalho  1 , Luciano Kleber de Souza Luna  2   3 , Klinger Soares Faíco-Filho  1 , Ana Helena Perosa  4 , Nancy Bellei  1
Affiliations
Comparative Study

Comparative analysis of three point-of-care lateral flow immunoassays for detection of anti-SARS-CoV-2 antibodies: data from 100 healthcare workers in Brazil

Danielle Dias Conte et al. Braz J Microbiol. 2021 Sep.

Abstract

Since the coronavirus disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by real-time RT-PCR is the gold standard but requires a certified laboratory infrastructure with high-cost equipment and trained personnel. However, for large-scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW) from São Paulo university hospital previously tested by RT-PCR: (1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), (2) Diagnostic Kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China), and (3) SARS-CoV-2 Antibody Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also analyzed by the number of days post symptoms (DPS) in three groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). The observed sensibility was 85.71%, 47.62%, and 44.05% for Bioclin, Wondfo, and Livzon, respectively, with a specificity of 100% for all LFIA. Bioclin was more sensitive (p<0.01), regardless of the DPS. Thus, the Bioclin may be used as a POC test to monitor SARS-CoV-2 seroconversion in HCW.

Keywords: COVID-19; Healthcare workers; Lateral flow immunoassay; Point-of-care; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Venn diagram showing the overlap between individual IgG and IgM reactivity for Bioclin and Livzon LFIAs. a, Bioclin. b, Livzon
See this image and copyright information in PMC

References

    1. WHO. Coronavirus disease 2019 (COVID-19), Situation Report –51 2020. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.
    1. WHO. Weekly epidemiological update - 2 February 2021: World Health Organization; 2021 [cited 2021 February 09]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update%2D....
    1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534. doi: 10.1016/S1473-3099(20)30120-1. - DOI - PMC - PubMed
    1. Vashist SK (2020) In vitro diagnostic assays for COVID-19: recent advances and emerging trends. Diagnostics (Basel) 10(4). 10.3390/diagnostics10040202 - PMC - PubMed
    1. Wang H, Ai J, Loeffelholz MJ, Tang YW, Zhang W. Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals. Emerg Microbes Infect. 2020;9(1):2200–2211. doi: 10.1080/22221751.2020.1826362. - DOI - PMC - PubMed